Novel therapies based on mechanisms of HIV-1 cell entry

N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Amino Acid Sequence
  • CD4 Antigens / drug effects
  • CD4-Positive T-Lymphocytes / physiology
  • Enfuvirtide
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / drug effects
  • HIV Envelope Protein gp120 / metabolism
  • HIV Envelope Protein gp41 / adverse effects
  • HIV Envelope Protein gp41 / therapeutic use
  • HIV Fusion Inhibitors / pharmacology
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Protease Inhibitors
  • HIV-1 / drug effects*
  • HIV-1 / metabolism
  • HIV-1 / physiology*
  • Humans
  • Membrane Fusion / drug effects*
  • Membrane Fusion / physiology*
  • Molecular Sequence Data
  • Peptide Fragments / adverse effects
  • Peptide Fragments / therapeutic use
  • Receptors, Chemokine / drug effects*
  • Receptors, Chemokine / metabolism
  • Reverse Transcriptase Inhibitors / metabolism
  • Viral Envelope Proteins / chemistry
  • Viral Envelope Proteins / metabolism

Substances

  • CD4 Antigens
  • HIV Envelope Protein gp120
  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • HIV Protease Inhibitors
  • Peptide Fragments
  • Receptors, Chemokine
  • Reverse Transcriptase Inhibitors
  • Viral Envelope Proteins
  • peptide T1249
  • Enfuvirtide